Neumora Therapeutics (NASDAQ:NMRA) Issues Earnings Results

Neumora Therapeutics (NASDAQ:NMRA) released its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.07), Briefing.com reports. During the same period in the prior year, the company earned ($1.14) earnings per share.

Neumora Therapeutics Stock Down 17.1 %

Shares of Neumora Therapeutics stock opened at $11.31 on Wednesday. The stock has a 50 day moving average price of $13.08 and a two-hundred day moving average price of $11.41. The stock has a market capitalization of $1.81 billion, a P/E ratio of -4.42 and a beta of 3.92. Neumora Therapeutics has a 12-month low of $8.33 and a 12-month high of $21.00.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NMRA. HC Wainwright started coverage on shares of Neumora Therapeutics in a research report on Tuesday, October 1st. They issued a “buy” rating and a $30.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $29.00 target price on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $21.67.

Insider Activity at Neumora Therapeutics

In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now owns 20,100 shares of the company’s stock, valued at $342,303. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares in the company, valued at approximately $342,303. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert A. Lenz sold 5,563 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now owns 322,966 shares in the company, valued at approximately $4,847,719.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 110,538 shares of company stock worth $1,390,513. 26.40% of the stock is owned by insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.